Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trametinib works in treating patients with juvenile
myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment
(refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.